Want to see GB:CTEC full AI Analyst Report?
CTEC Stock Chart & Stats
216.00 p
4.20 p(1.94%)
At close: 4:00 PM EDT
216.00 p
4.20 p(1.94%)
Day’s Range― - ―
52-Week Range193.00 p - 259.30 p
Previous CloseN/A
Volume4.45M
Average Volume (3M)6.27M
Market Cap
£4.37B
Enterprise Value5.45K
Total Cash (Recent Filing)£99.51M
Total Debt (Recent Filing)£1.75B
Price to Earnings (P/E)34.6
Beta1.13
Next Earnings
Feb 23, 2027EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend Yield2.4%
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,954,852,000
10 Day Avg. Volume5,278,857
30 Day Avg. Volume6,266,139
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£301.40Price Target Upside39.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.2
Revenue Forecast (FY)£2.56B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Diversified CategoriesConvaTec's core business is built on recurring consumables across four clinical categories (wound, ostomy, continence, infusion). That mix creates predictable repeat demand supported by reimbursement and clinical pathways, underpinning durable revenue visibility, stable cash flow and resilience to short-term volume swings.
Improving Operating ProfitabilityOperating and EBITDA margin expansion over recent years reflects sustained cost control and better mix, which boosts structural earnings quality. Higher margins increase free cash flow potential and provide buffer for reinvestment into growth CapEx and clinical launches, supporting medium-term profitability targets.
Infusion Growth And Validated Product PipelineInfusion Care momentum (management expects double-digit H2 growth) plus clinical evidence and reimbursement for ConvaNiox strengthen structural growth prospects. Targeted growth CapEx (~USD 90m) to expand infusion capacity ties investment to visible demand, supporting sustainable mid-term organic growth and product-led market share gains.
Bears Say
Elevated LeverageLeverage has increased materially, reducing financial flexibility and raising sensitivity to earnings or rate shocks. Even with management targets to reduce leverage, higher debt constrains strategic optionality (M&A, aggressive buybacks) and increases refinancing and interest risk over the medium term if earnings or cash flow underperform.
Multi-year FDA RemediationA multi-year remediation program creates ongoing execution and compliance risk. Although no current safety impact is reported, remediation diverts management focus and resources, can slow regulatory approvals or product launches, and adds implementation risk that could affect production, costs and revenue growth over the next 12–24 months.
InnovaMatrix Sales Collapse & ImpairmentThe sharp drop in InnovaMatrix sales and a large non-cash impairment highlight product commercialisation risk in the wound portfolio. This reduced near-term revenue and depressed margins, forcing the company to rely more on other categories and new launches to hit growth targets, increasing pressure on execution and pipeline delivery.
ConvaTec News
CTEC FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest share price was 193.00 p and its highest was 259.30 p in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is £4.37B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Feb 23, 2027 which is in 200 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Aug 04, 2026. The company reported 0.063 p earnings per share for the quarter, beating the consensus estimate of 0.062 p by 0.001 p.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of 3.973 p which represents an annual dividend yield of 2.4%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.09.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of 0.063 p in its last earnings report, beating expectations of 0.062 p. Following the earnings report the stock price went up 1.775%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in GB:CTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£301.40 (39.54% Upside)
£301.40 (39.54% Upside)
Insider Transactions
Bought Shares
Worth £263.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
2.40%
Trailing 12-Months
Asset Growth
3.64%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
CTEC Stock 12 Month Forecast
Average Price Target
301.40 p
▲(39.54% Upside)